Business
Cellular and Molecular Life Sciences Publication
Cellular and Molecular Life Sciences Publication.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 2592R\n Faron Pharmaceuticals Oy\n 03 November 2021\n \n \n \n \n Faron Pharmaceuticals Ltd.\n \n \n (\"Faron\")\n \n \n \n \n \n \n Cellular and Molecular Life Sciences\n \n \n Publishes Research on Inhibition of Vascular Adhesion Protein-1 \n \n \n \n Enabling the Expansion of Hematopoietic Stem Cells \n \n \n \n \n \n \n \n \n Company announcement, November 3, 2021\n \n \n \n \n \n \n TURKU, FINLAND / BOSTON, MA\n \n \n \n \n - Faron Pharmaceuticals Ltd. (\n AIM: FARN, First North: FARON\n ), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the multidisciplinary journal Cellular and Molecular Life Sciences recently published research showing the inhibition of Vascular Adhesion Protein\n ‑\n 1 (VAP-1) potentially supports the expansion of human hematopoietic stem cells (HSC). The full manuscript titled, \"Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation,\" can be accessed online at: \n \n \n https://link.springer.com/article/10.1007%2Fs00018-021-03977-6\n \n \n .\n \n \n \n \n \n The published research aligns with Faron's pre-clinical findings through its ongoing Haematokine program (expansion of hematopoietic stem cells by regulating enzymatic activity of VAP-1). The study demonstrates that an investigational AOC3 inhibitor that targets VAP-1 and blocks its enzymatic activity has the potential to benefit a variety of conditions where an expansion of hematopoietic stem cells is needed. This includes hematopoietic stem cell transplantation, where approximately 25% of transplants fail due to poor expansion of transplanted cells. \n \n \n \n \n \n \"Our research shows for the first time that Vascular Adhesion Protein\n ‑\n 1 serves as a check point-like inhibitor, restricting the expansion of hematopoietic stem cells,\" said Sirpa Jalkanen, Academician and Professor of Immunology, University of Turku. \"Similar to what we have seen with immune checkpoint inhibitors, we believe that inhibiting the enzymatic activity of Vascular Adhesion Protein\n ‑\n 1 enables the expansion of hematopoietic stem cells, which are essential to the f...